Time trends, factors associated with, and reasons for COVID-19 vaccine hesitancy: A massive online survey of US adults from January-May 2021.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 24 08 2021
accepted: 15 11 2021
entrez: 21 12 2021
pubmed: 22 12 2021
medline: 27 1 2022
Statut: epublish

Résumé

COVID-19 vaccine hesitancy has become a leading barrier to increasing the US vaccination rate. To evaluate time trends in COVID-19 vaccine intent during the US vaccine rollout, and identify key factors related to and self-reported reasons for COVID-19 vaccine hesitancy in May 2021. A COVID-19 survey was offered to US adult Facebook users in several languages yielding 5,088,772 qualifying responses from January 6 to May 31, 2021. Data was aggregated by month. Survey weights matched the sample to the age, gender, and state profile of the US population. Demographics, geographic factors, political/COVID-19 environment, health status, beliefs, and behaviors. "If a vaccine to prevent COVID-19 were offered to you today, would you choose to get vaccinated." Hesitant was defined as responding probably or definitely would not choose to get vaccinated (versus probably or definitely would, or already vaccinated). COVID-19 vaccine hesitancy decreased by one-third from 25.4% (95%CI, 25.3, 25.5) in January to 16.6% (95% CI, 16.4, 16.7) in May, with relatively large decreases among participants with Black, Pacific Islander or Hispanic race/ethnicity and ≤high school education. Independent risk factors for vaccine hesitancy in May (N = 525,644) included younger age, non-Asian race, < 4 year college degree, living in a more rural county, living in a county with higher Trump vote share in the 2020 election, lack of worry about COVID-19, working outside the home, never intentionally avoiding contact with others, and no past-year flu vaccine. Differences in hesitancy by race/ethnicity varied by age (e.g., Black adults more hesitant than White adults <35 years old, but less hesitant among adults ≥45 years old). Differences in hesitancy by age varied by race/ethnicity. Almost half of vaccine hesitant respondents reported fear of side effects (49.2% [95%CI, 48.7, 49.7]) and not trusting the COVID-19 vaccine (48.4% [95%CI, 48.0, 48.9]); over one-third reported not trusting the government, not needing the vaccine, and waiting to see if safe. Reasons differed by degree of vaccine intent and by race/ethnicity. COVID-19 vaccine hesitancy varied by demographics, geography, beliefs, and behaviors, indicating a need for a range of messaging and policy options to target high-hesitancy groups.

Identifiants

pubmed: 34932583
doi: 10.1371/journal.pone.0260731
pii: PONE-D-21-27471
pmc: PMC8691631
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0260731

Subventions

Organisme : NCIRD CDC HHS
ID : U01 IP001121
Pays : United States

Déclaration de conflit d'intérêts

Drs. King, Mejia and Mr. Rubenstein have no conflict of interest to report. Dr. Reinhart received salary support from an unrestricted gift from Facebook described in the funding section of the paper.

Références

Ann Intern Med. 2020 Dec 15;173(12):964-973
pubmed: 32886525
Vaccine. 2020 Sep 29;38(42):6500-6507
pubmed: 32863069
JAMA Netw Open. 2020 Oct 1;3(10):e2025197
pubmed: 33084902
JAMA Netw Open. 2021 Sep 1;4(9):e2127582
pubmed: 34591103
JAMA. 2020 Dec 29;:
pubmed: 33372943
Proc Natl Acad Sci U S A. 2021 Dec 21;118(51):
pubmed: 34903656
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Int J Environ Res Public Health. 2021 Sep 20;18(18):
pubmed: 34574827
N Engl J Med. 2020 Sep 17;383(12):e77
pubmed: 32706952
JAMA Netw Open. 2021 Jul 1;4(7):e2117074
pubmed: 34264327
JAMA. 2021 Jun 15;325(23):2397-2399
pubmed: 34028495
Science. 2021 Jun 4;372(6546):1092-1097
pubmed: 33927057
PLoS Med. 2020 Sep 22;17(9):e1003379
pubmed: 32960880
MMWR Morb Mortal Wkly Rep. 2021 Jun 25;70(25):928-933
pubmed: 34166337
Cell. 2020 Sep 3;182(5):1077-1092
pubmed: 32846157
Prev Med Rep. 2021 Dec;24:101569
pubmed: 34603943
BMC Med Res Methodol. 2003 Oct 20;3:21
pubmed: 14567763

Auteurs

Wendy C King (WC)

Department of Epidemiology, Graduate School of Public Health University of Pittsburgh, Pittsburgh, PA, United States of America.

Max Rubinstein (M)

Department of Statistics & Data Science, Carnegie Mellon University, Pittsburgh, PA, United States of America.
Heinz College, Carnegie Mellon University, Pittsburgh, PA, United States of America.

Alex Reinhart (A)

Department of Statistics & Data Science, Carnegie Mellon University, Pittsburgh, PA, United States of America.

Robin Mejia (R)

Department of Statistics & Data Science, Carnegie Mellon University, Pittsburgh, PA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH